Investing.com - Pacific Biosciences (NASDAQ: PACB) reported fourth quarter EPS of $-0.27, $0.01 better than the analyst estimate of $-0.28. Revenue for the quarter came in at $58.36M versus the consensus estimate of $56.96M.
Pacific Biosciences's stock price closed at $6.67. It is down -20.60% in the last 3 months and down -38.24% in the last 12 months.
Pacific Biosciences saw 1 positive EPS revisions and 2 negative EPS revisions in the last 90 days. See Pacific Biosciences's stock price’s past reactions to earnings here.
According to InvestingPro, Pacific Biosciences's Financial Health score is "fair performance".
Check out Pacific Biosciences's recent earnings performance, and Pacific Biosciences's financials here.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar